TD
Neural

Tauroursodeoxycholic Acid

CAS 14605-22-2

Overview

Research context and commercial specification.

A conjugated bile acid with a well-established function as a chemical chaperone, assisting protein folding in the endoplasmic reticulum and buffering proteotoxic stress. Tauroursodeoxycholic acid is studied across hepatic, metabolic and neurodegenerative research, where it is used as a probe of cellular stress response rather than as a target-specific agent. It anchors the portfolio's interest in how cells respond when repair becomes the priority.

Research direction

Incidence on the axisEndoplasmic-reticulum stress & cellular protection
PositioningThe stress-response active
ER stressCytoprotection

At a glance

CAS number14605-22-2
INCI nameTauroursodeoxycholic Acid
Molecular formulaC26H45NO6S
Molecular weight499.70 g/mol
Purity≥98.0%
AppearanceWhite powder
GradePharma grade / Research grade
SolubilityFreely soluble in water and ethanol
StorageCool, dry, protected from light — 25 °C
Shelf life36 months unopened
Packaging25 kg / drum
OriginBile-acid derived, multi-stage purification
Analytical methodsHPLC (purity, assay) · LC-MS (identity) · Residual solvents (GC)
CertificationISO 9001 · GMP

Published references

This library is synchronized from PubMed and shows bibliographic metadata only (title, authors, journal, year, link). No abstract or full text is reproduced. Papers flagged as context-dependent are included for scientific completeness and require careful interpretation.

  • Front Immunol2026Context-dependent — read with care
    Kohoutova D, Shur J, Terlizzo M, et al.
    Case Series: Severe cholangitis as an immune checkpoint inhibitor induced adverse event in four cases: management and treatment options including tocilizumab and ursodeoxycholic acid.
    This paper reports associations or intervention outcomes in a specific model or population. It is presented for research context only and is not a claim about any finished product.
    Open in PubMed →
  • Front Pharmacol2026Context-dependent — read with care
    Chao R, Zhang Y, Hao Y, et al.
    Hepatoprotective mechanism of tauroursodeoxycholic acid and its therapeutic potential in liver diseases.
    This paper reports associations or intervention outcomes in a specific model or population. It is presented for research context only and is not a claim about any finished product.
    Open in PubMed →
  • Hepatology2026Context-dependent — read with care
    Kowdley KV, Lawitz E, Bowlus CL, et al.
    Treatment with elafibranor to normalize alkaline phosphatase in patients with primary biliary cholangitis and incomplete response to ursodeoxycholic acid: Results from the phase III randomized controlled ELSPIRE trial.
    This paper reports associations or intervention outcomes in a specific model or population. It is presented for research context only and is not a claim about any finished product.
    Open in PubMed →
  • Int J Mol Sci2026
    Mousavi SM, Ozmen SN, Adedokun MA, et al.
    Reassessment of Neuroprotective Efficacy of TUDCA in Ischemic Stroke: A Multi-Model In Vivo and In Vitro Study.
    Open in PubMed →

Technical questions

What is tauroursodeoxycholic acid?
TUDCA is a conjugated bile acid with an established function as a chemical chaperone in the endoplasmic reticulum, where it assists protein folding and buffers cellular stress.
How is it supplied?
As a bile-acid-derived powder at ≥98.0% purity, freely soluble in water and ethanol, with residual-solvent testing included in the batch release panel and a 36-month unopened shelf life.
Which application contexts is it positioned in?
Cellular stress and cytoprotection work, metabolic-wellness formulations, and liver-directed nutrition — where it is studied as a probe of stress response rather than as a target-specific agent.

Ask about this active

Request the complete specification dossier, a sample, or formulation guidance for Creatrich Biotech actives.

Get in touch →